{"id":"NCT00713310","sponsor":"Warner Chilcott","briefTitle":"Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents With Active Ulcerative Colitis","officialTitle":"Study to Assess the Safety and Efficacy of Asacol® (1.2 to 4.8 g/Day) Administered as 400 mg Delayed-release Tablets Given Every 12 Hours for 6 Weeks to Children and Adolescents With Mildly-to-Moderately Active Ulcerative Colitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-12","primaryCompletion":"2011-03","completion":"2011-03","firstPosted":"2008-07-11","resultsPosted":"2012-04-04","lastUpdate":"2012-04-05"},"enrollment":83,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Ulcerative Colitis"],"interventions":[{"type":"DRUG","name":"Asacol 400 mg","otherNames":[]},{"type":"DRUG","name":"Asacol 400 mg","otherNames":[]}],"arms":[{"label":"Low-Dose","type":"EXPERIMENTAL"},{"label":"High-Dose","type":"EXPERIMENTAL"}],"summary":"The overall objective of this study is to assess the safety and efficacy of high dose and low dose Asacol administered as 400 mg delayed-release tablets given every 12 hours for 6 weeks to children and adolescents with mildly-to-moderately active ulcerative colitis.","primaryOutcome":{"measure":"Treatment Success PUCAI (Pediatric Ulcerative Colitis Activity Index), mITT/Modified Intent to Treat Population","timeFrame":"Baseline and 6 weeks","effectByArm":[{"arm":"Low Dose","deltaMin":56.1,"sd":null},{"arm":"High Dose","deltaMin":55,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.9240"}]},"eligibility":{"minAge":"5 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":42,"countries":["United States","Canada","Croatia","Poland","Romania"]},"refs":{"pmids":["25419597"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":41},"commonTop":["Nasopharyngitis","Colitis Ulcerative","Headache","Fatigue","Dizziness"]}}